DGIdb - TRIMIPRAMINE Drug Record

TRIMIPRAMINE chembl:CHEMBL644 Approved

Alternate Names:

IL-6001
TRIMIPRAMINE
SURMONTIL
7162-RP
TRIMEPROPRIMINE
7162 RP
SAPILENT
TRIMEPRIMINE
RP-7162
5-(GAMMA-DIMETHYLAMINO-BETA-METHYLPROPYL)-10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPINE
5-[3-(DIMETHYLAMINO)-2-METHYLPROPYL]-10,11-DIHYDRO-5H-DIBENZ[B,F]AZEPINE
10,11-DIHYDRO-N,N,BETA-TRIMETHYL-5H-DIBENZ[B,F]AZEPINE-5-PROPANAMINE
BETA-METHYLIMIPRAMINE
SURMONTIL®
chemidplus:739-71-9
rxcui:10834
drugbank:00726
chembl:CHEMBL644
pubchem.compound:5584

Drug Info:

Drug Class	antidepressive agents, tricyclic
Year of Approval	1979
FDA Approval	1979
Drug Class	small molecule
Drug Indications	Antidepressive Agents, Tricyclic

(4 More Sources)

Publications:

Leathart JB et al., 1998, CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles., Pharmacogenetics
Dalén P et al., 1998, 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes., Clin Pharmacol Ther
Dahl ML et al., 1996, Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype., Psychopharmacology (Berl)
Nielsen KK et al., 1994, Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms., Clin Pharmacol Ther
Hicks JK et al., 2013, Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants., Clin Pharmacol Ther
de Vos A et al., 2011, Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients., Pharmacogenomics J
Forget P et al., 2008, Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study., J Pain Symptom Manage
Koski A et al., 2007, A fatal doxepin poisoning associated with a defective CYP2D6 genotype., Am J Forensic Med Pathol
Schenk PW et al., 2008, Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients., Mol Psychiatry
Johnson M et al., 2006, A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment., CNS Spectr
Stephan PL et al., 2006, Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity., Pharmacopsychiatry
Goetz MP et al., 2005, Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes., J Clin Oncol
Koski A et al., 2006, CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies., Forensic Sci Int
Tacke U et al., 1992, Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations., J Clin Psychopharmacol
Vandel P et al., 2004, Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients., Hum Psychopharmacol
Steimer W et al., 2004, Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers., Clin Chem
Furman KD et al., 2004, Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics., Pharmacogenetics
Roberts RL et al., 2004, No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline., Hum Psychopharmacol
Kirchheiner J et al., 2003, Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity., Pharmacogenetics
Kirchheiner J et al., 2003, Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics., J Clin Psychopharmacol
Dahl ML et al., 1992, Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population., Clin Pharmacol Ther
Kirchheiner J et al., 2002, Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers., Pharmacogenetics
Murphy GM Jr et al., 2001, CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression., Neuropsychopharmacology
Eap CB et al., 2000, Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients., Ther Drug Monit
1999, Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG)., Clin Pharmacol Ther
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
Haenisch B et al., 2011, Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters., Psychopharmacology (Berl)
Diamond et al., 2006, Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade., Eur Neuropsychopharmacol
Berger et al., 1996, Trimipramine: a challenge to current concepts on antidepressives., Eur Arch Psychiatry Clin Neurosci
Wang JH et al., 2001, Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19., Clin Pharmacol Ther
Morinobu S et al., 1997, Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy., Psychiatry Clin Neurosci
Koyama E et al., 1996, Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients., J Clin Psychopharmacol
Brøsen K et al., 1995, A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype., Pharmacogenetics
de Morais SM et al., 1994, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans., J Biol Chem
De Morais SM et al., 1994, Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese., Mol Pharmacol
Swen JJ et al., 2011, Pharmacogenetics: from bench to byte--an update of guidelines., Clin Pharmacol Ther
Sibbing D et al., 2010, Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy., J Thromb Haemost
Sibbing D et al., 2010, Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement., Circulation
Schenk PW et al., 2010, The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients., Pharmacogenomics J
Rudberg I et al., 2008, Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients., Eur J Clin Pharmacol
Rudberg I et al., 2008, Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients., Clin Pharmacol Ther
Sim SC et al., 2006, A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants., Clin Pharmacol Ther
Grasmäder K et al., 2004, Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting., Eur J Clin Pharmacol
Desta Z et al., 2002, Clinical significance of the cytochrome P450 2C19 genetic polymorphism., Clin Pharmacokinet

TRIMIPRAMINE SLC6A2

Interaction Score: 1.14

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
17016423 17139284 9537821 21484238

Sources:
TdgClinicalTrial TEND GuideToPharmacology
TRIMIPRAMINE SLC6A4

Interaction Score: 0.68

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

Specific Action of the Ligand Inhibition

PMIDs:
9537821 16388933

Sources:
TdgClinicalTrial TEND GuideToPharmacology
TRIMIPRAMINE CYP2D6

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9918137 9585799 8867869 8181196 23486447 20531370 18359183 17721180 17667959 17008819 16871470 16361630 16024198 1527229 15252821 15205367 15115913 14716707 14646691 14520122 1346258 12360109 11682257 10774635 10460069

Sources:
PharmGKB FDA
TRIMIPRAMINE CYP2C19

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23486447 14520122 11452243 10774635 9316174 8835703 8563772 8195181 7969038 21412232 20531370 20492469 20083681 19884907 18677622 17625515 16413245 15168101 12222994

Sources:
PharmGKB
TRIMIPRAMINE SLC6A3

Interaction Score: 0.27

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
9537821

Sources:
GuideToPharmacology
TRIMIPRAMINE DRD1

Interaction Score: 0.1

Interaction Types & Directionality:

binder

Interaction Info:

PMIDs:
8863001

Sources:
DTC
TRIMIPRAMINE CBX1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIMIPRAMINE CYP2C9

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14520122

Sources:
PharmGKB

TdgClinicalTrial: TRIMIPRAMINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antidepressive Agents, Tricyclic

Drug Class small molecule

FDA Approval 1979

Publications:
TEND: TRIMIPRAMINE
- Version: 01-August-2011
Alternate Names:

Drug Info:

Year of Approval 1979

Drug Class antidepressive agents, tricyclic

Publications:

PharmGKB: trimipramine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Rudberg I et al., 2008, Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients., Eur J Clin Pharmacol

de Vos A et al., 2011, Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients., Pharmacogenomics J

Brøsen K et al., 1995, A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype., Pharmacogenetics

DTC: TRIMIPRAMINE
- Version: 02-September-2020
Alternate Names:

CHEMBL644 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Trimipramine
- Version: 2020.06.01
Alternate Names:

D00HZV TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL644
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
GuideToPharmacology: 178103890
- Version: 29-September-2020
Alternate Names:

Drug Info:

Publications:
FDA: Trimipramine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

Novel drug target	Established target
Trial Name	-
Specific Action of the Ligand	Inhibition

TRIMIPRAMINE Drug Record

TRIMIPRAMINE chembl:CHEMBL644 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

PMIDs: 17016423 17139284 9537821 21484238

Sources: TdgClinicalTrial TEND GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name - Specific Action of the Ligand Inhibition

PMIDs: 9537821 16388933

Sources: TdgClinicalTrial TEND GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9918137 9585799 8867869 8181196 23486447 20531370 18359183 17721180 17667959 17008819 16871470 16361630 16024198 1527229 15252821 15205367 15115913 14716707 14646691 14520122 1346258 12360109 11682257 10774635 10460069

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23486447 14520122 11452243 10774635 9316174 8835703 8563772 8195181 7969038 21412232 20531370 20492469 20083681 19884907 18677622 17625515 16413245 15168101 12222994

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 9537821

Sources: GuideToPharmacology

Interaction Types & Directionality: binder

Interaction Info:

PMIDs: 8863001

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14520122

Sources: PharmGKB

TdgClinicalTrial: TRIMIPRAMINE

Alternate Names:

Drug Info: Drug Indications Antidepressive Agents, Tricyclic Drug Class small molecule FDA Approval 1979

Publications:

TEND: TRIMIPRAMINE

Alternate Names:

Drug Info: Year of Approval 1979 Drug Class antidepressive agents, tricyclic

Publications:

PharmGKB: trimipramine

Alternate Names:

Drug Info:

DTC: TRIMIPRAMINE

Alternate Names: CHEMBL644 ChEMBL Drug ID

Drug Info:

Publications:

TTD: Trimipramine

Alternate Names: D00HZV TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL644

Alternate Names:

Drug Info:

Publications:

GuideToPharmacology: 178103890

Alternate Names:

Drug Info:

Publications:

FDA: Trimipramine

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
17016423 17139284 9537821 21484238

Sources:
TdgClinicalTrial TEND GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

Specific Action of the Ligand Inhibition

PMIDs:
9537821 16388933

Sources:
TdgClinicalTrial TEND GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
9918137 9585799 8867869 8181196 23486447 20531370 18359183 17721180 17667959 17008819 16871470 16361630 16024198 1527229 15252821 15205367 15115913 14716707 14646691 14520122 1346258 12360109 11682257 10774635 10460069

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
23486447 14520122 11452243 10774635 9316174 8835703 8563772 8195181 7969038 21412232 20531370 20492469 20083681 19884907 18677622 17625515 16413245 15168101 12222994

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
9537821

Sources:
GuideToPharmacology

Interaction Types & Directionality:

binder

PMIDs:
8863001

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
14520122

Sources:
PharmGKB

Drug Info:

Drug Indications Antidepressive Agents, Tricyclic

Drug Class small molecule

FDA Approval 1979

Drug Info:

Year of Approval 1979

Drug Class antidepressive agents, tricyclic

Alternate Names:

CHEMBL644 ChEMBL Drug ID

Alternate Names:

D00HZV TTD Drug ID